U.K.-based seed investor Lifearc Ventures is celebrating a second major deal from its portfolio of companies after Abbvie Inc. bought the tiny former “garage startup" DJS Antibodies Ltd. for $255 million up front plus undisclosed milestone payments. DJS’ lead program is DJS-002, a potential first-in-class lysophosphatidic acid receptor 1 antagonist in preclinical studies for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases.
Chiesi Farmaceutici SpA has described new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Hpvac SA has announced new data on its lead compound Hpvac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.
T-cell activation and function depend on Ca2+ signals and Ca2+ influx after antigen binding to the T-cell receptor (TCR) is mediated by store-operated Ca2+ entry (SOCE) through Ca2+ release-activated Ca2+ (CRAC) channels in the plasma membrane.
Chiesi Farmaceutici SpA has patented discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Humanwell Healthcare (Group) Co. Ltd. has disclosed G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, autoimmune and metabolic diseases, among others.
Chiesi Farmaceutici SpA has synthesized Janus kinase inhibitors, particularly JAK1, JAK2, JAK3 and nonreceptor tyrosine-protein kinase TYK2 inhibitors, reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.
Idorsia Pharmaceuticals Ltd. has described cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.
Researchers from National Institute of Health Sciences (Japan) have published data from a study that aimed to identify novel biomarkers for the diagnosis of diffuse alveolar damage (DAD), a drug-induced interstitial lung disease (DILD) associated with a poor prognosis.
RSS
